The overall objective of this proposal is to delineate prognostic markers for ZIP4-mediated cachexia in lethal pancreatic cancer (PC). Understanding these markers is critical to therapeutic interventions for PC patients suffering from muscle wasting. Cachectic muscle wasting is frequently associated with PC. Current therapies aimed at the cancer cells provide little benefit in reducing cachexia and improving patient survival, highlighting the importance of finding new prognostic biomarkers for muscle wasting and developing new therapy targeting muscle catabolism in PC. The new concept in this proposal is that ZIP4, a zinc transporter highly expressed in PC, is a key regulator of PC growth, muscle wasting and survival. We have been working on the role of ZIP4 in PC for many years. Our group is the first one to show that ZIP4 is overexpressed in a majority of PC patients (>80%) and contributes to PC pathogenesis. Silencing ZIP4 sensitizes PC cells to chemotherapy and zinc deficiency-induced apoptosis, and prolongs survival, which suggests that ZIP4 is a prognostic marker and therapeutic target for PC. Our recent studies suggest that ZIP4 mediates muscle wasting in PC. However, how ZIP4 promotes muscle wasting is not clear. In this proposal, on the basis of our recent findings we aim to determine the prognostic value of ZIP4, identify ZIP4-activated catabolic mediators, and elucidate the mechanism(s) through which ZIP4 mediates muscle wasting in PC. In our newly developed surgical xenograft mouse model, we observed that surgical removal of tumors combined with lowering ZIP4 levels in PC cells significantly improved survival and reduced body weight loss and muscle wasting. We also demonstrated that reduced ZIP4 levels in PC cells ameliorated muscle wasting due to attenuated p38 MAPK activation and subsequent atrogin1/MAFbx up regulation, which was shown previously to mediate the muscle catabolism induced by other types of tumor cells. The central hypothesis of the proposed study is that ZIP4 mediates PC-induced muscle wasting through a distinctly enhanced activation of the p38 MAPK-mediated catabolic pathway by increasing expression and release of specific heat shock proteins and this ZIP4-enhanced cachexia pathway could serve as a prognostic marker for this dismal disease.
Three specific aims are proposed: We will evaluate the prognostic values of ZIP4 and related catabolic pathway in PC by examining the correlation of ZIP4 in resected tumors with serum Hsp70/90 levels, p38 MAPK-activated catabolic pathway in muscles and clinical outcome (survival) of PC patients. We will determine whether PC induces muscle wasting in two independent mouse models of PC cachexia through ZIP4-dependent expression/release of Hsp70 and Hsp90. We will delineate the mechanisms of PC induced muscle wasting through Hsp70/90 activation of p38 MAPK-mediated muscle catabolism. ZIP4-induced cachexia represents a novel signaling pathway impacting PC growth and survival. The proposed studies will help define the mechanism regulating this oncogenic axis and evaluate the prognostic value of the ZIP4-cachexia axis in PC. This study will have an immediate impact for PC patients.

Public Health Relevance

Pancreatic cancer (PC) is one of the most difficult human cancers to treat due to the inability to detect disease at an early stage and the lack of effective therapies. This proposal aims to study the role of ZIP4, a new marker and therapeutic target in pancreatic cancer, in the biology of these tumors, and the function in PC-induced muscle wasting and cachexia. This study will lead to meaningful advances for understanding this horrible disease and help in the development of novel therapeutic and diagnostic approaches for this malignancy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA203108-01
Application #
9052445
Study Section
Clinical Oncology Study Section (CONC)
Program Officer
Spalholz, Barbara A
Project Start
2016-02-01
Project End
2016-06-30
Budget Start
2016-02-01
Budget End
2016-06-30
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Zhou, Feifan; Yang, Jingxuan; Zhang, Yuqing et al. (2018) Local Phototherapy Synergizes with Immunoadjuvant for Treatment of Pancreatic Cancer through Induced Immunogenic Tumor Vaccine. Clin Cancer Res 24:5335-5346